PharmaEssentia Corp (藥華醫藥) has welcomed a German Supreme Court ruling that it said “set aside” damages it was ordered to pay in a contract dispute with an Austrian drug developer.
At the same time, the Austrian company, AOP Orphan Pharmaceuticals GmbH, said the ruling validated part of its position in the dispute and vowed to continue to pursue damages for breach of contract.
In a filing with the Taiwan Stock Exchange late on Tuesday, PharmaEssentia said it had been notified by its German counsel that the German Federal Court of Justice decided to set aside an unfavorable order to the company by the International Chamber of Commerce (ICC) in 2020.
The ICC had ruled that PharmaEssentia should pay an arbitral award of 142 million euros (US$161.5 million) to AOP for improperly trying to terminate a license agreement for a new blood cancer drug.
However, the German court seemed to agree, at least to a certain extent, with PharmaEssentia’s argument that the award was greatly inflated, because it was based on incomplete information and procedurally flawed.
PharmaEssentia said that as a result of the Supreme Court ruling, it “is not ordered to pay AOP damages and to reimburse its costs.”
The court also did not refer the case back to the Higher Regional Court or the arbitral tribunal, said PharmaEssentia, a global pharmaceutical company founded by a group of Taiwanese-American scientists in 2003.
That meant “the decision of the arbitral tribunal is thus finally dropped,” an outcome that “has a positive impact on the company,” PharmaEssentia and its lawyers said
However, the Austrian company expressed a different view of the court’s ruling, arguing that “the decision has no implication regarding the merits of AOP’s claims against PharmaEssentia and will only result in protracted further proceedings.”
The German court upheld the award finding the PharmaEssentia-AOP deal valid and PharmaEssentia liable for certain damages, and it also dismissed all of PharmaEssentia counterclaims against it, AOP said.
AOP did acknowledge that the court “found procedural flaws with respect to product supply and damage quantification, impacting the damages awarded.”
AOP Health Group founder and board member Rudolf Widmann said the company was disappointed that the court found flaws in the reasoning regarding damages.
“We have no doubt that we will ultimately also recover these confirmed damages in further proceedings. We will take all necessary steps in due course to have this ultimately confirmed by an enforceable arbitral award,” he said.
The two companies inked a deal in 2008 to develop the blood cancer drug Besremi, but the agreement began to sour in the years that followed, and PharmaEssentia attempted to terminate the agreement.
AOP claimed it was being forced to renegotiate the deal on less favorable terms, with PharmaEssentia alleging that AOP was refusing to recognize its obligation to share data about the drug.
AOP started the arbitration in Frankfurt, Germany, before an ICC tribunal in 2018, which sided with AOP and issued its 142 million euros award in 2020.
‘SWASTICAR’: Tesla CEO Elon Musk’s close association with Donald Trump has prompted opponents to brand him a ‘Nazi’ and resulted in a dramatic drop in sales Demonstrators descended on Tesla Inc dealerships across the US, and in Europe and Canada on Saturday to protest company chief Elon Musk, who has amassed extraordinary power as a top adviser to US President Donald Trump. Waving signs with messages such as “Musk is stealing our money” and “Reclaim our country,” the protests largely took place peacefully following fiery episodes of vandalism on Tesla vehicles, dealerships and other facilities in recent weeks that US officials have denounced as terrorism. Hundreds rallied on Saturday outside the Tesla dealership in Manhattan. Some blasted Musk, the world’s richest man, while others demanded the shuttering of his
ADVERSARIES: The new list includes 11 entities in China and one in Taiwan, which is a local branch of Chinese cloud computing firm Inspur Group The US added dozens of entities to a trade blacklist on Tuesday, the US Department of Commerce said, in part to disrupt Beijing’s artificial intelligence (AI) and advanced computing capabilities. The action affects 80 entities from countries including China, the United Arab Emirates and Iran, with the commerce department citing their “activities contrary to US national security and foreign policy.” Those added to the “entity list” are restricted from obtaining US items and technologies without government authorization. “We will not allow adversaries to exploit American technology to bolster their own militaries and threaten American lives,” US Secretary of Commerce Howard Lutnick said. The entities
Minister of Finance Chuang Tsui-yun (莊翠雲) yesterday told lawmakers that she “would not speculate,” but a “response plan” has been prepared in case Taiwan is targeted by US President Donald Trump’s reciprocal tariffs, which are to be announced on Wednesday next week. The Trump administration, including US Secretary of the Treasury Scott Bessent, has said that much of the proposed reciprocal tariffs would focus on the 15 countries that have the highest trade surpluses with the US. Bessent has referred to those countries as the “dirty 15,” but has not named them. Last year, Taiwan’s US$73.9 billion trade surplus with the US
Prices of gasoline and diesel products at domestic gas stations are to fall NT$0.2 and NT$0.1 per liter respectively this week, even though international crude oil prices rose last week, CPC Corp, Taiwan (台灣中油) and Formosa Petrochemical Corp (台塑石化) said yesterday. International crude oil prices continued rising last week, as the US Energy Information Administration reported a larger-than-expected drop in US commercial crude oil inventories, CPC said in a statement. Based on the company’s floating oil price formula, the cost of crude oil rose 2.38 percent last week from a week earlier, it said. News that US President Donald Trump plans a “secondary